1. Home
  2. SKWD vs LQDA Comparison

SKWD vs LQDA Comparison

Compare SKWD & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SKWD
  • LQDA
  • Stock Information
  • Founded
  • SKWD 2007
  • LQDA 2004
  • Country
  • SKWD United States
  • LQDA United States
  • Employees
  • SKWD N/A
  • LQDA N/A
  • Industry
  • SKWD Property-Casualty Insurers
  • LQDA Biotechnology: Pharmaceutical Preparations
  • Sector
  • SKWD Finance
  • LQDA Health Care
  • Exchange
  • SKWD Nasdaq
  • LQDA Nasdaq
  • Market Cap
  • SKWD 2.3B
  • LQDA 2.5B
  • IPO Year
  • SKWD 2023
  • LQDA 2018
  • Fundamental
  • Price
  • SKWD $48.64
  • LQDA $28.05
  • Analyst Decision
  • SKWD Buy
  • LQDA Strong Buy
  • Analyst Count
  • SKWD 12
  • LQDA 10
  • Target Price
  • SKWD $64.20
  • LQDA $37.40
  • AVG Volume (30 Days)
  • SKWD 353.2K
  • LQDA 2.5M
  • Earning Date
  • SKWD 10-29-2025
  • LQDA 11-03-2025
  • Dividend Yield
  • SKWD N/A
  • LQDA N/A
  • EPS Growth
  • SKWD 3.25
  • LQDA N/A
  • EPS
  • SKWD 3.37
  • LQDA N/A
  • Revenue
  • SKWD $1,335,358,000.00
  • LQDA $69,216,000.00
  • Revenue This Year
  • SKWD $19.98
  • LQDA $424.31
  • Revenue Next Year
  • SKWD $25.51
  • LQDA $359.32
  • P/E Ratio
  • SKWD $14.43
  • LQDA N/A
  • Revenue Growth
  • SKWD 22.27
  • LQDA 343.41
  • 52 Week Low
  • SKWD $41.28
  • LQDA $9.71
  • 52 Week High
  • SKWD $65.05
  • LQDA $29.94
  • Technical
  • Relative Strength Index (RSI)
  • SKWD 57.90
  • LQDA 62.88
  • Support Level
  • SKWD $44.23
  • LQDA $26.60
  • Resistance Level
  • SKWD $50.67
  • LQDA $28.09
  • Average True Range (ATR)
  • SKWD 1.65
  • LQDA 2.13
  • MACD
  • SKWD 0.42
  • LQDA 0.35
  • Stochastic Oscillator
  • SKWD 73.40
  • LQDA 84.19

About SKWD Skyward Specialty Insurance Group Inc.

Skyward Specialty Insurance Group Inc is a specialty insurance company that delivers commercial property and casualty products and solutions on a non-admitted and admitted basis. The firm has one reportable segment through which it offers a broad array of insurance coverages to several market niches. It operates multiple lines of business, including general liability, excess liability, professional liability, commercial auto, group accident, health, property, surety, and workers' compensation.

About LQDA Liquidia Corporation

Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.

Share on Social Networks: